Kyle Gano sold $9.2M of NBIX
Chief Executive Officer at NEUROCRINE BIOSCIENCES INC. 65,000 shares at an average of $141.50, traded Jan 15, 2025, filed Jan 17, 2025.
Score components
- +25RoleCEO
- +25Trade size$9.2M at market
- +10Share of holdings soldSold 46% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000914475-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 15, 2025 | MOption exercise Common Stock10b5-1 | +4,812 | $32.99 | $159k | 140,204 | Jan 17, 2025 |
| Jan 15, 2025 | SOpen-market sale Common Stock10b5-1 | -4,812 | $141.50 | $681k | 135,392 | Jan 17, 2025 |
| Jan 15, 2025 | MOption exercise Common Stock10b5-1 | +60,188 | $32.99 | $2.0M | 195,580 | Jan 17, 2025 |
| Jan 15, 2025 | SOpen-market sale Common Stock10b5-1 | -60,188 | $141.50 | $8.5M | 135,392 | Jan 17, 2025 |
| Jan 15, 2025 | MOption exercise Incentive Stock Optionderivative10b5-1 | -4,812 | $0.00 | $0 | 0 | Jan 17, 2025 |
| Jan 15, 2025 | MOption exercise Non-Qualified Stock Optionderivative10b5-1 | -60,188 | $0.00 | $0 | 0 | Jan 17, 2025 |
Related signals
Other insiders at NEUROCRINE BIOSCIENCES INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 32Weak | NEUROCRINE BIOSCIENCES INC | Matt Abernethy Chief Financial Officer | $363k 2,311 shares | -5% | |
| 21Weak | NEUROCRINE BIOSCIENCES INC | David W. Boyer Chief Corp. Affairs Officer | $130k 826 shares | -9% | |
| 10Weak | NEUROCRINE BIOSCIENCES INC | Eric Benevich Chief Commercial Officer | $333k 2,154 shares | -3% | |
| 10Weak | NEUROCRINE BIOSCIENCES INC | Kevin Charles Gorman director | $13M 106,322 shares | -17% | |
| 0Weak | NEUROCRINE BIOSCIENCES INC | Ingrid Delaet Chief Regulatory Officer | $62k 457 shares | -9% | |
| 20Weak | NEUROCRINE BIOSCIENCES INC | Kevin Charles Gorman director | $1.2M 9,613 shares | -2% | |
| 15Weak | NEUROCRINE BIOSCIENCES INC | William H Rastetter director | $3.3M 30,000 shares | -44% | |
| 16Weak | NEUROCRINE BIOSCIENCES INC | Matt Abernethy Chief Financial Officer | $299k 2,558 shares | -7% | |
| 8Weak | NEUROCRINE BIOSCIENCES INC | Eric Benevich Chief Commercial Officer | $251k 2,154 shares | -5% | |
| 17Weak | NEUROCRINE BIOSCIENCES INC | David W. Boyer Chief Corp. Affairs Officer | $208k 1,785 shares | -47% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.